Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating Safety and Efficacy of GI-XBI-302 in Patients With Glucocorticoid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

NCT05094765 is registered in ClinicalTrials.gov with Shenzhen Xbiome Biotech Co., Ltd. as lead sponsor.

NCT NCT05094765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05094765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating Safety and Efficacy of GI-XBI-302 in Patients With Glucocorticoid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Lead sponsor
Shenzhen Xbiome Biotech Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
November 1, 2021
Completion date
March 2, 2023
Enrollment
15 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gvhd